Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forgotten costs of systemic lupus erythematosus: estimating indirect healthcare costs in a national prospective observational Canadian lupus cohort.

Lupus science & medicine·2026
Same author

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Journal of clinical epidemiology·2026
Same author

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality.

Annals of the rheumatic diseases·2025
Same author

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Towards a minimal core dataset for systemic lupus erythematosus studies.

Lupus science & medicine·2025
Same author

An educational tool to improve PREeclamPsia knowledge and Aspirin adheRence in lupus prEgnancies: the PREPARE trial.

Rheumatology (Oxford, England)·2025

Related Experiment Video

Updated: Jun 19, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Demystifying neuropsychiatric lupus--is it possible?

John G Hanly1

  • 1Division of Rheumatology, Department of Medicine and Department of Pathology, Capital Health and Dalhousie University, Halifax, Nova Scotia, Canada. john.hanly@cdha.nshealth.ca

Bulletin of the NYU Hospital for Joint Diseases
|October 27, 2009
PubMed
Summary

Diagnosing and treating nervous system issues in systemic lupus erythematosus (SLE) is difficult. Recent advances in understanding autoimmune mechanisms and neuroimaging are improving the diagnosis and treatment of neuropsychiatric (NP) SLE.

Related Experiment Videos

Last Updated: Jun 19, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

  • Neurology
  • Rheumatology
  • Immunology

Background:

  • Nervous system events in systemic lupus erythematosus (SLE) present diagnostic and therapeutic challenges.
  • Clinical manifestations are diverse, complicating attribution to SLE versus other causes.
  • Limited clinical trial data hinders optimal treatment selection for neuropsychiatric (NP) events.

Purpose of the Study:

  • To review the current understanding of neuropsychiatric (NP) events in SLE.
  • To highlight recent advancements in classification, attribution, and pathogenetic mechanisms.
  • To discuss the emerging consensus on the pathogenesis and treatment of NP-SLE.

Main Methods:

  • Review of recent literature on NP events in SLE.
  • Analysis of neuroimaging studies.
  • Elucidation of autoimmune and inflammatory mechanisms.

Main Results:

  • Increased rigor in classifying and attributing NP events over the past decade.
  • Emerging insights into the pathogenetic mechanisms of NP-SLE.
  • Growing consensus on the understanding and management of NP-SLE.

Conclusions:

  • Despite ongoing challenges, significant progress has been made in understanding NP-SLE.
  • Neuroimaging and autoimmune research are crucial for advancing NP-SLE management.
  • An emerging consensus offers a path forward for diagnosis and treatment.